Streetbeat News

NRXS

NeurAxis, Inc.

https://neuraxis.com

Industry

Biotechnology

NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.

Open

3.34

Mkt cap

22M

Volume

7.8K

High

3.41

P/E Ratio

-1.41

52-wk high

3.89

Low

3.12

Div yield

N/A

52-wk low

2.00

NeurAxis has announced the publication of a medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS) with a Blue Cross Blue Shield license in Florida. This development could potentially expand the market for NeurAxis' medical devices.

Portfolio Pulse from Benzinga Newsdesk

May 16, 2024 | 1:07 pm

NeurAxis, a biotechnology firm, has announced that its innovative medical treatments will now be covered under new medical policy in North Dakota. This expansion into North Dakota represents a significant step for NeurAxis in increasing the accessibility of its treatments.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 1:10 pm

Earnings reports for April 9, 2024, include a mix of projected losses and gains across various sectors. Tilray Brands, Cognyte Software, and Nauticus Robotics are expected to report losses, while Neogen, SMART Global Holdings, WD-40, and Pricesmart anticipate profits. Other companies like Neuraxis, Greenidge Generation, and Aehr Test Systems will also report their financial outcomes.

Portfolio Pulse from Benzinga Insights

April 09, 2024 | 9:35 am

NeurAxis, Inc. (NYSE:NRXS), a medical technology company, announced that Blue Cross and Blue Shield of Kansas City (BCBSKC) will now cover its neuromodulation therapies, expanding its coverage to approximately 9.25 million individuals. This development is part of NeurAxis's commercial strategy to leverage clinical evidence for its IB-Stim technology to obtain payer coverage and drive market adoption.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 2:07 pm

NeurAxis, Inc. (NRXS) issued a shareholder letter highlighting progress since its IPO, including strong med-tech research publications, insurance policy coverage, and revenue growth in Massachusetts and Wisconsin. The company anticipates two new revenue opportunities in 2024: Functional Dyspepsia treatment and an exclusive license for a rectal expulsion device (RED) from the University of Michigan. Both have a $2B market opportunity. NeurAxis is preparing for FDA clearance submissions and expects to surpass 75M covered lives and significant revenue increases in 2024.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 2:11 pm

Neuraxis reported a decrease in Q3 earnings per share (EPS) from $(1.14) to $(1.35) year-over-year (YoY), and a 22.84% drop in sales from $618.80K to $477.46K YoY.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 10:46 pm

NeurAxis, identified by its ticker NRXS, has successfully raised $3 million in financing by offering preferred stock at a price of $2.38 per share. This capital infusion could be used to fund the company's operations, development, and potential expansion.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 2:10 pm

NeurAxis (NYSE:NRXS) announced the results of a comparative study of adolescent patients with functional abdominal pain disorders (FAPD) treated with IB-Stim™ therapy or standard of care medications. The study concluded that IB-Stim™ may be a good non-pharmacologic alternative for FAPD. The study showed that IB-Stim™ therapy showed improvements in abdominal pain and functional disability compared to baseline, while amitriptyline showed improvements in abdominal pain. IB-Stim™ was more effective than cyproheptadine in improving abdominal pain and did not differ from amitriptyline.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 1:21 pm

Neuraxis (AMEX:NRXS) reported Q2 losses of $(1.21) per share, a 39.08% decrease YoY. Sales also decreased by 5.36% to $646.00K compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 12:13 pm

Several stocks experienced significant price movements in Tuesday's mid-day session. Tenon Medical withdrew its proposed public offering, causing its shares to climb 63.5%. Avalo Therapeutics agreed to divest AVTX-800 series, leading to a 52.6% gain. Cognyte Software reported better-than-expected Q2 results and issued FY24 guidance above estimates, resulting in a 24.8% gain. Xos was awarded a contract by the State of California, causing a 23% gain. The Beauty Health Company announced a business transformation program and a $100 million share repurchase, leading to a 16.6% jump. On the other hand, Acelyrin shares fell 60.8% after announcing disappointing trial results. CS Disco shares fell 22.1% after the company announced its CEO's departure.

Portfolio Pulse from Lisa Levin

September 12, 2023 | 5:44 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.